Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1-34 in the Treatment of Osteoporosis in Men and Postmenopausal Women
- 1 July 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 17 (7) , 1151-1161
- https://doi.org/10.1359/jbmr.2002.17.7.1151
Abstract
No abstract availableThis publication has 60 references indexed in Scilit:
- The Bone-Building Action of the Parathyroid HormoneDrugs & Aging, 1999
- Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosisPublished by Elsevier ,1997
- Anabolic effect of high doses of human parathyroid hormone (1–38) in mature intact female ratsJournal of Bone and Mineral Research, 1994
- Anabolic effects of parathyroid hormone on cortical bone in ovariectomized ratsBone, 1994
- Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in ratsJournal of Bone and Mineral Research, 1993
- Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25-dihydroxyvitamin DJournal of Bone and Mineral Research, 1986
- Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.BMJ, 1980
- PRIMARY HYPERPARATHYROIDISM: CHANGES IN THE PATTERN OF CLINICAL PRESENTATIONThe Lancet, 1980
- Primary HyperparathyroidismNew England Journal of Medicine, 1980
- ANABOLIC EFFECT OF LOW DOSES OF A FRAGMENT OF HUMAN PARATHYROID HORMONE ON THE SKELETON IN POSTMENOPAUSAL OSTEOPOROSISThe Lancet, 1976